Mumbai, April 3 -- The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Acetaminophen Injection, 500 mg/50 mL (10 mg/mL) and 1000 mg/100 mL (10 mg/mL), of B. Braun Medical, Inc.

This product is indicated for the management of mild to moderate pain in adult and pediatric patients aged 2 years and older, as well as moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients aged 2 years and older.

According to IQVIA, the product had US sales of approximately $55 million for the twelve months ending February 2025. The company expects to launch this product through its marketing partner in the near future.

Gland Pharma is one of the largest and fastest-growing injecta...